Results Wire: US FDA Advisory Committee Unanimously Supports Novartis’ Cosentyx (Secukinumab) for Psoriasis and Gives Input on Optimal Dosing - OCT 20, 2014 (DODAC)
On Monday, October 20, 2014 the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) unanimously supported, by a vote of 7-Yes to 0-No, the approval of Novartis’ Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.